ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

rocakinogene sifuplasmid

Also written as “INO-9012”, “INO-9112” and “INO-4212 + INO-9012”.

Its studies are mostly in Glioblastoma · Carcinoma, Transitional Cell · Hepatitis B · Hemorrhagic Fever, Ebola · Breast Neoplasms, led by 2 companies.

Drug pageRocakinogene sifuplasmid: every studyAll 10 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Apr 2, 20188 company-led studies, 3 open or runningNext primary completion: Dec 31, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Inovio Pharmaceuticalsits history only61 open or runningphase 2since Apr 2, 2018Sep 11, 2014Dec 31, 2027phase 2 · NCT03491683
Geneos Therapeutics22 open or runningphase 2since Jan 27, 2020Jan 27, 2020Sep 2029phase 2 · NCT07722741

Also a collaborator on its studies: GeneOne Life Science.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Geneos Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2019Named rocakinogene sifuplasmidINNProposed as its International Nonproprietary Name in WHO's List 122 · before, INO-9012, INO-9112
  2. Jan 27, 2020First study: phase 2 study in HCCFirst studyNCT04251117 · 36 enrolled · United States, New Zealand
  3. Jul 20, 2026Phase 2 study in HCCNCT07722741 · 90 planned · United States, New Zealand

Ahead

  1. Sep 2029Primary completion: phase 2 study in HCCNCT07722741

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Geneos Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07722741HCC · United States, New Zealand2RecruitingSep 202990
NCT04251117HCC · United States, New Zealand2Active, not recruitingNov 29, 202436

How it is read

Names in the registry

  • “INO-9012”, 5 entries
  • “INO-9112”, 1 entry
  • “INO-4212 + INO-9012”, 1 entry
  • “INO-4201 + INO-9012”, 1 entry
  • “INO-3106, INO-9012”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.